Dr. Deirdre Cohen on Emerging Agents in Gastric Cancer

Deirdre J. Cohen, MD
Published: Wednesday, Apr 06, 2016



Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

Inhibitors have been developed in gastric cancer to target both HER2 and VEGF, Cohen explains. These agents provide meaningful survival benefits for patients, she adds. In addition to other agents in development, Cohen says there is an explosion of studies investigating immunotherapy agents.

An expansion phase Ib study looked at the PD-1 inhibitor pembrolizumab (Keytruda) in patients with PD-L1–positive tumors. Results showed an overall response rate of approximately 22% and a median time to response of 8 weeks, she says. A second phase Ib study examined avelumab as second-line and maintenance therapy, which also demonstrated encouraging responses. Phase III data is needed to confirm these findings.


Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

Inhibitors have been developed in gastric cancer to target both HER2 and VEGF, Cohen explains. These agents provide meaningful survival benefits for patients, she adds. In addition to other agents in development, Cohen says there is an explosion of studies investigating immunotherapy agents.

An expansion phase Ib study looked at the PD-1 inhibitor pembrolizumab (Keytruda) in patients with PD-L1–positive tumors. Results showed an overall response rate of approximately 22% and a median time to response of 8 weeks, she says. A second phase Ib study examined avelumab as second-line and maintenance therapy, which also demonstrated encouraging responses. Phase III data is needed to confirm these findings.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x